Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T0757 |
Omeprazole
Losec,Prilosec,奥美拉唑,奥美拉挫,H 16868,Antra |
Proton pump; Phospholipase; Antibacterial; Autophagy | Autophagy; Membrane transporter/Ion channel; Metabolism; Microbiology/Virology |
Omeprazole (Losec) 是一种质子泵抑制剂,有研究胃肠道疾病的潜力。它竞争性抑制 CYP2C19活性,Ki 为 2 到 6 μM。它还抑制革兰氏阳性菌和革兰氏阴性菌生长。它是中性鞘磷脂酶的外泌体抑制剂。 | |||
T12309 |
Omeprazole metabolite Omeprazole sulfone
Omeprazole sulphone,Omeprazole sulfone |
Others | Others |
Omeprazole metabolite Omeprazole sulfone 是Omeprazole 的代谢物,能够抑制质子泵。 | |||
T2687 |
Omeprazole sulfide
Omeprazole metabolite Omeprazole sulfide,Ufiprazole,奥美拉唑硫醚 |
Proton pump; Drug Metabolite | Membrane transporter/Ion channel; Metabolism |
Omeprazole sulfide (Ufiprazole) 是 Omeprazole 的代谢物。 | |||
T10138 |
4-Desmethoxy Omeprazole
|
Drug Metabolite | Metabolism |
4-Desmethoxy Omeprazole 是 Omeprazole 的活性代谢物。Omeprazole 是质子泵抑制剂。Omeprazole 竞争性抑制 CYP2C19 活性,Ki=2 - 6 μM。Omeprazole 还抑制革兰氏阴性菌和革兰氏阳性菌生长。 | |||
T22391 |
Omeprazole Sodium
|
P450; Proton pump; Antibacterial; Autophagy | Autophagy; Membrane transporter/Ion channel; Metabolism; Microbiology/Virology |
Omeprazole 是有效的质子泵抑制剂,在胃肠道疾病的研究中具有价值。它竞争性抑制CYP2C19活性,Ki 为 2 到 6 μM。它还抑制革兰氏阴性菌和革兰氏阳性菌生长。它是中性鞘磷脂酶的外泌体抑制剂。 | |||
T2686 |
Esomeprazole Magnesium
(S)-Omeprazole magnesium,NEXIUM,埃索美拉唑镁,(-)-Omeprazole magnesium |
ATPase; Proton pump | Membrane transporter/Ion channel |
Esomeprazole Magnesium (NEXIUM) 是一种口服有效的 H+, K+-ATPase 抑制剂,在上消化道疾病和胃食管反流疾病中具有研究价值。Esomeprazole magnesium 是一种外泌体抑制剂,通过抑制 V-H+-ATPases 来阻断外泌体的释放。 | |||
T2686L |
Esomeprazole Sodium
埃索美拉唑钠,(S)-Omeprazole sodium |
ATPase; Proton pump | Membrane transporter/Ion channel |
Esomeprazole Sodium ((S)-Omeprazole sodium) 是一种口服有效的活性质子泵抑制剂。Esomeprazole sodium 通过抑制胃壁细胞中的 H+, K+-ATPase 来降低酸分泌,在胃食管反流疾病中有研究价值。Esomeprazole 是一种外泌体抑制剂,通过抑制 V-H+-ATPases 来阻断外泌体的释放。 | |||
T68250 | Omeprazole magnesium | ||
Omeprazole magnesium 是口服活性的质子泵(proton pump)抑制剂(PPI),用于抑制胃酸,常用于研究胃酸反流和烧心症相关症状。 | |||
T37659 |
5-hydroxy Omeprazole
|
||
5-hydroxy Omeprazole is a major metabolite of omeprazole , an inhibitor of the gastric H+/K+-ATPase pump.[1] 5-hydroxy Omeprazole is produced from omeprazole by the action of cytochrome P450 (CYP) isoform 2C19, a monooxygenase. [2][3] CYP2C19 polymorphisms significantly influence the metabolism of omeprazole, and individuals may be classified as homozygous extensive metabolizers, heterozygous extensive metabolizers, and poor metabolizers.[1] | |||
T12308 |
Omeprazole-d3
奥美拉挫 D3,H 16868 D3 |
Others | Others |
Omeprazole D3 is deuterium labeled Omeprazole. Omeprazole is a proton pump inhibitor (PPI) | |||
T71980 |
Omeprazole acid
|
||
Omeprazole acid is a medication used in the treatment of gastroesophageal reflux disease, peptic ulcer disease, and Zollinger–Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. Omeprazole is a proton pump inhibitor and as such blocks the release of stomach acid. | |||
T36840 |
(R)-Omeprazole (sodium salt)
|
||
(R)-Omeprazole is the inactive isomer of omeprazole , a gastric proton-pump inhibitor. A stereoselective hydroxylation of (R)-omeprazole is mediated primarily by cytochrome P450 (CYP) 2C19, whereas CYP3A4 favors sulfoxidation of the active (S)-enantiomer . (R)-Omeprazole has been shown to act as a reversible direct-acting and metabolism-dependent inhibitor of CYP2C19 in pooled human liver microsomes (IC50 = 8.1 μM). | |||
T8386 |
Esomeprazole Magnesium trihydrate
埃索美拉唑镁三水合物,埃索美拉唑镁(三水),(S)-Omeprazole magnesium trihydrate |
Proton pump | Membrane transporter/Ion channel |
Esomeprazole Magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) 是一种口服有效的H+, K+-ATPase 抑制剂,在上消化道疾病和胃食管反流疾病的研究中具有价值。它是一种外泌体抑制剂,通过抑制 V-H+-ATPases 来阻断外泌体的释放。 | |||
T66287 |
(R)-Omeprazole
|
||
(R)-Omeprazole 是一种有用的有机化合物,可用于生命科学领域的相关研究。其产品编号为 T66287,CAS号为 119141-89-8。 | |||
T20626 |
Esomeprazole
|
Proton pump; Cysteine Protease | Membrane transporter/Ion channel; Proteases/Proteasome |
Esomeprazole 是奥美拉唑(omeprazole) 的S-异构体,抑制溶酶体半胱氨酸蛋白酶legumain,防止癌症转移。它是一种质子泵抑制剂(PPI)。 | |||
T71259 |
GNE-900
GNE900,GNE 900 |
Apoptosis; Chk | Apoptosis; Cell Cycle/Checkpoint |
GNE-900 是一种 ATP 竞争性、选择性和口服活性 ChK1抑制剂,对 ChKl,ChK2的 IC50值分别为为 0.0011,1.5 µM。GNE-900 废除 G2-M 检查点,增强 DNA 损伤,并诱导胞凋亡 (Apoptosis)。gemcitabine 和 GNE-900 给药显示抗肿瘤活性[1]< /sup>。 | |||
T68303 | Esomeprazole strontium | ||
Esomeprazole strontium is a gastric proton pump inhibitor. | |||
T61667 |
Esomeprazole potassium salt
|
||
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is an effective and orally active proton pump inhibitor that works by inhibiting the H+, K+-ATPase enzyme in the gastric parietal cells, leading to a reduction in acid secretion. It is a promising compound for investigating symptomatic gastroesophageal reflux disease [1] [2] [3]. | |||
T61740 |
Esomeprazole hemistrontium
|
||
Esomeprazole hemistrontium, also known as (S)-Omeprazole, is a potent and orally active proton pump inhibitor that effectively reduces acid secretion by inhibiting the H+, K+-ATPase in gastric parietal cells. This compound exhibits promising potential for research in symptomatic gastroesophageal reflux disease [1] [2] [3]. | |||
T61467 |
Esomeprazole magnesium salt
|
||
Esomeprazole magnesium salt is a potent and orally active proton pump inhibitor that effectively reduces acid secretion in gastric parietal cells by inhibiting the H+, K+-ATPase. This compound has shown promise for the research and treatment of symptomatic gastroesophageal reflux disease [1][2][3]. | |||
T23667 |
AGN-201904
AGN201904,AGN 201904 |
ATPase | Membrane transporter/Ion channel |
AGN-201904 是质子泵抑制剂,是一种奥美拉唑前药,可延缓衰老,可用于预防和治疗消化性溃疡。 | |||
T27669 |
JNJ-26070109
JNJ26070109 |
||
JNJ-26070109, an antagonist of cholecystokinin CCK2 receptor, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. | |||
T26577 |
AGN-201904Z
AGN-201904-Z,AGN-201904 |
||
AGN-201904Z is a slowly absorbed, acid-stable pro-proton pump inhibitor (pro-PPI) rapidly converted to omeprazole in the systemic circulation giving a prolonged residence time. AGN 201904-Z produced a significantly greater, and nocturnal acid suppression |